Anti-platelet therapy in diabetic hypertensive patients with and without cardiovascular diseases in Palestine, from 2003 to 2008

There has been an improvement in anti-platelet therapy using aspirin for primary prevention among high risk patients. No significant change was observed for secondary prevention over the five years. Efforts are needed to enhance the use of aspirin particularly for cardiovascular patients requiring secondary prevention.